BACKGROUND: In immunocompromised patients with pulmonary infiltrates, transbronchial lung biopsies (TBB) obtained by forceps has been shown to increase the diagnostic yield over simple bronchoalveolar lavage. Cryo-TBB is a novel modality for obtaining lung biopsies. We aimed to evaluate for the first time the efficacy and safety of cryo-TBB in immunocompromised patients. METHODS: Fifteen immunocompromised patients with pulmonary infiltrates underwent cryo-TBB. During the procedure two to three biopsy samples were taken. Procedure characteristics, complications, and the diagnostic yield were retrospectively evaluated. RESULTS: Most patients (n = 11) were immunocompromised due to hematological malignancies. The remaining four patients were receiving chronic immunosuppressive treatment due to previous solid-organ transplantation (n = 2) or collagen-vascular disease (n = 2). No major complications occurred in the cryo-TBB group. The mean surface area of the specimen taken by cryo-TBB was 9 mm(2). The increase in surface area and quality of biopsy samples translated to a high percentage of alveolated tissue (70 %) that enabled a clear histological detection of the following diagnoses: noncaseating granulomatous inflammation (n = 2), acute interstitial pneumonitis consistent with drug reaction (n = 5), nonspecific interstitial pneumonia fibrotic variant (n = 1), diffuse alveolar damage (n = 3), organizing pneumonia (n = 3), and pulmonary cryptococcal pneumonia (n = 1). Diagnostic information obtained by cryo-TBB led to change in the management of 12 patients (80 %). CONCLUSION: Cryo-TBB in immunocompromised patients with pulmonary infiltrates provides clinically important diagnostic data with a low complication rate. These advantages should be further compared with traditional forceps TBB in a prospective randomized trial.
BACKGROUND: In immunocompromised patients with pulmonary infiltrates, transbronchial lung biopsies (TBB) obtained by forceps has been shown to increase the diagnostic yield over simple bronchoalveolar lavage. Cryo-TBB is a novel modality for obtaining lung biopsies. We aimed to evaluate for the first time the efficacy and safety of cryo-TBB in immunocompromised patients. METHODS: Fifteen immunocompromised patients with pulmonary infiltrates underwent cryo-TBB. During the procedure two to three biopsy samples were taken. Procedure characteristics, complications, and the diagnostic yield were retrospectively evaluated. RESULTS: Most patients (n = 11) were immunocompromised due to hematological malignancies. The remaining four patients were receiving chronic immunosuppressive treatment due to previous solid-organ transplantation (n = 2) or collagen-vascular disease (n = 2). No major complications occurred in the cryo-TBB group. The mean surface area of the specimen taken by cryo-TBB was 9 mm(2). The increase in surface area and quality of biopsy samples translated to a high percentage of alveolated tissue (70 %) that enabled a clear histological detection of the following diagnoses: noncaseating granulomatous inflammation (n = 2), acute interstitial pneumonitis consistent with drug reaction (n = 5), nonspecific interstitial pneumonia fibrotic variant (n = 1), diffuse alveolar damage (n = 3), organizing pneumonia (n = 3), and pulmonary cryptococcal pneumonia (n = 1). Diagnostic information obtained by cryo-TBB led to change in the management of 12 patients (80 %). CONCLUSION:Cryo-TBB in immunocompromised patients with pulmonary infiltrates provides clinically important diagnostic data with a low complication rate. These advantages should be further compared with traditional forceps TBB in a prospective randomized trial.
Authors: J Hetzel; R Eberhardt; F J F Herth; C Petermann; G Reichle; L Freitag; I Dobbertin; K J Franke; F Stanzel; T Beyer; P Möller; P Fritz; G Ott; P A Schnabel; H Kastendieck; W Lang; A T Morresi-Hauf; M N Szyrach; R Muche; P L Shah; A Babiak; M Hetzel Journal: Eur Respir J Date: 2011-08-18 Impact factor: 16.671
Authors: Christian Schumann; Jürgen Hetzel; Alexander J Babiak; Tobias Merk; Thomas Wibmer; Peter Möller; Philipp M Lepper; Martin Hetzel Journal: J Thorac Cardiovasc Surg Date: 2010-03-11 Impact factor: 5.209
Authors: Robert J Lentz; A Christine Argento; Thomas V Colby; Otis B Rickman; Fabien Maldonado Journal: J Thorac Dis Date: 2017-07 Impact factor: 2.895
Authors: Frédéric Rivière; Aurélie Cazes; Olivier Bylicki; Hervé Le Floch; Wanda Gaspard; Marie Alice Cornetto; France Charton; Jacques Margery; Frédéric Grassin Journal: Indian J Thorac Cardiovasc Surg Date: 2022-01-23
Authors: Marcos J Las Heras; Jose Dianti; Manuel Tisminetzky; Graciela Svetliza; Sergio E Giannasi; Eduardo San Roman Journal: J Intensive Care Soc Date: 2019-05-07